AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ALTERITY THERAPEUTICS LTD

0.460

-0.020-4.17%

Volume:79.72K

Turnover:37.35K

Market Cap:100.05M

PE:-4.14

High:0.480

Open:0.480

Low:0.460

Close:0.480

52wk High:0.785

52wk Low:0.350

Shares:217.51M

Float Shares:149.50M

Volume Ratio:8.80

T/O Rate:0.05%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.111

EPS(LYR):-0.111

ROE:-54.98%

ROA:-34.08%

PB:2.34

PE(LYR):-4.14

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Alterity Therapeutics Director Peter Ashley Marks Acquires 47,620 Shares for $0.50 Each, Valued at $23,810

Alterity Therapeutics Issues 8,400,000 Shares Tied to Exercised Options at A$ 0.5 Each

Alterity Therapeutics CEO to Join Cantor Global Healthcare Conference Fireside Chat

Alterity Therapeutics Enters Underwriting Agreement for Exercise of up to 8.4 Million Listed Options

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/ATH.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATH.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ATH.AU\",,,,,undefined,":{"symbol":"ATH.AU","market":"AU","secType":"STK","nameCN":"ALTERITY THERAPEUTICS LTD","latestPrice":0.46,"timestamp":1789085483429,"preClose":0.48,"halted":0,"volume":79721,"delay":0,"changeRate":-0.04166666666666659,"nameEN":"ALTERITY THERAPEUTICS LTD","floatShares":149498066,"shares":217508326,"eps":-0.1112,"marketStatus":"Trading","change":-0.02,"latestTime":"09-11 10:14:32 AEST","open":0.48,"high":0.48,"low":0.46,"amount":37348,"amplitude":0.041667,"askPrice":0.47,"askSize":102291,"bidPrice":0.46,"bidSize":46280,"shortable":3,"etf":0,"ttmEps":-0.1112,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789106400000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.48,"openAndCloseTimeList":[[1789084800000,1789106400000]],"volumeRatio":8.804994,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"ATH.AU","preClose":0.48,"auctionPrice":0.48,"auctionVolume":696,"auctionTime":1789084741231,"referenceTime":1789036203090,"auction":1,"marketStatus":"盘前竞价","timestamp":1789084741231}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ATH.AU\",,,,,undefined,":{"symbol":"ATH.AU","floatShares":149498066,"roa":"-34.08%","roe":"-54.98%","lyrEps":-0.1112,"volumeRatio":8.804994,"shares":217508326,"dividePrice":0,"high":0.48,"amplitude":0.041667,"preClose":0.48,"low":0.46,"week52Low":0.35,"pbRate":"2.34","psRate":"27.72","week52High":0.785,"institutionHeld":0,"latestPrice":0.46,"committee":-0.376998,"eps":-0.1112,"divideRate":0,"volume":79721,"delay":0,"ttmEps":-0.1112,"open":0.48,"prevYearClose":0.4,"prevWeekClose":0.5,"prevMonthClose":0.505,"prevQuarterClose":0.575,"fiveDayClose":0.5,"twentyDayClose":0.545,"sixtyDayClose":0.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATH.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2026-06-03","symbol":"ATH.AU","defaultRemindTime":1780444800000,"type":"split","dateTimestamp":1780408800000,"forFactor":50,"toFactor":1,"ratio":50}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATH.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATH.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666130814","title":"Alterity Therapeutics Director Peter Ashley Marks Acquires 47,620 Shares for $0.50 Each, Valued at $23,810","url":"https://stock-news.laohu8.com/highlight/detail?id=2666130814","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666130814?lang=en_us&edition=fundamental","pubTime":"2026-09-09 07:02","pubTimestamp":1788908538,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics director Peter Ashley Marks acquires 47,620 shares for $0.50 each, valued at $23,810Alterity Therapeutics director Peter Ashley Marks increased indirect ownership via Lampam Pty ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL7NngY5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Alterity Therapeutics Director Peter Ashley Marks Acquires 47,620 Shares for $0.50 Each, Valued at $23,810","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665321597","title":"Alterity Therapeutics Issues 8,400,000 Shares Tied to Exercised Options at A$ 0.5 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2665321597","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665321597?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:04","pubTimestamp":1788861886,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics issues 8,400,000 shares tied to exercised options at A$ 0.5 eachAlterity Therapeutics completed the issuance of 8,400,000 fully paid ordinary shares to MST Financial Services, in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL4Xqvyq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664875580","title":"Alterity Therapeutics CEO to Join Cantor Global Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2664875580","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664875580?lang=en_us&edition=fundamental","pubTime":"2026-09-03 18:04","pubTimestamp":1788429842,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics CEO to join Cantor Global Healthcare Conference fireside chatAlterity Therapeutics CEO David Stamler will join a fireside chat at the Cantor Global Healthcare Conference on Sept. 11, 2026.The session is scheduled for 10:20 a.m. ET.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDLb4T9BH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663602953","title":"Alterity Therapeutics Enters Underwriting Agreement for Exercise of up to 8.4 Million Listed Options","url":"https://stock-news.laohu8.com/highlight/detail?id=2663602953","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663602953?lang=en_us&edition=fundamental","pubTime":"2026-08-31 10:44","pubTimestamp":1788144243,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics  entered into an underwriting agreement with MST Financial Services, under which MST Financial agreed to underwrite the exercise of up to a total of 8.4 million unexercised ATHO listed options ahead of their expiry, according to a Monday Australian bourse filing.There are currently 15.9 million listed ATHO options on issue, exercisable at AU$0.50 and due to expire on Tuesday. MST Financial agreed to underwrite any shortfall arising from options not exercised by optionholders before the expiry date, up to a maximum of 8.4 million options. It will subscribe, or procure subscriptions, for a corresponding number of new fully paid ordinary shares in the firm.MST Financial will receive an underwriting fee of 7% of the gross proceeds raised from the exercise of options underwritten by it.The options are expected to raise around AU$4.2 million before costs, and the proceeds are expected to support continued late-stage clinical development of its ATH434 candidate in multip","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","BK4007","BK4539","BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":14,"pageCount":1,"totalSize":56,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ATH.AU\",params:#limit:6,delay:true,,,undefined,":[]}}